We Ran A Stock Scan For Earnings Growth And Shenzhen New Industries Biomedical Engineering (SZSE:300832) Passed With Ease
We Ran A Stock Scan For Earnings Growth And Shenzhen New Industries Biomedical Engineering (SZSE:300832) Passed With Ease
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. Loss-making companies are always racing against time to reach financial sustainability, so investors in these companies may be taking on more risk than they should.
對於初學者來說,購買那些向投資者講述好故事的公司看起來可能是一個好主意(也是一個令人興奮的前景),即使它當前缺乏營收和利潤的記錄。不幸的是,這些高風險的投資通常幾乎沒有任何回報的可能性,許多投資者爲此而付出代價。虧損企業始終在爭分奪秒地追求實現財務可持續性,因此這些公司的投資者可能承擔了比他們應承擔的風險要大。
If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Shenzhen New Industries Biomedical Engineering (SZSE:300832). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Shenzhen New Industries Biomedical Engineering with the means to add long-term value to shareholders.
如果這種公司不符合您的風格,您喜歡創業板公司,甚至是盈利的公司,那麼您可能會對深圳新產業生物醫藥股份有限公司(SZSE:300832)感興趣。即使這家公司的市場價值相當,投資者也會認爲,持續盈利將繼續爲深圳新產業生物醫藥股份有限公司提供爲股東增加長期價值的手段。
How Quickly Is Shenzhen New Industries Biomedical Engineering Increasing Earnings Per Share?
深圳新產業生物醫藥股份有限公司的每股收益在多快地增長?
Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Shareholders will be happy to know that Shenzhen New Industries Biomedical Engineering's EPS has grown 19% each year, compound, over three years. As a general rule, we'd say that if a company can keep up that sort of growth, shareholders will be beaming.
一般來說,每股收益(EPS)增長的公司也應該在股價上看到類似的趨勢。因此,有很多投資者喜歡買入EPS增長的公司的股票。股東們會很高興地知道,深圳新產業的每股收益每年累計增長19%,長達三年。總的來說,如果一家公司能保持這樣的增長率,股東們就會開心得合不攏嘴。
One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. Shenzhen New Industries Biomedical Engineering maintained stable EBIT margins over the last year, all while growing revenue 28% to CN¥4.1b. That's progress.
檢查一家公司的增長的一個方法是看它的營業收入和利潤前利息稅折舊攤銷(EBIT)利潤率的變化。深圳新產業去年保持了穩定的EBIT利潤率,同時營業收入增長了28%,達到了4100000000元人民幣。這是一個進步。
In the chart below, you can see how the company has grown earnings and revenue, over time. To see the actual numbers, click on the chart.
在下面的圖表中,您可以看到公司的盈利和營業收入隨時間的增長情況。要查看實際數字,請單擊圖表。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240724/0-09ca69c40266147cb4111744db38d7d4-0-6377eac33901542eea73bd1032d4a574.png/big)
You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for Shenzhen New Industries Biomedical Engineering's future profits.
你不會一邊開車一邊看後視鏡,所以你可能更感興趣的是這份免費報告,顯示了分析師對深圳新產業生物醫藥股份有限公司未來利潤的預測。
Are Shenzhen New Industries Biomedical Engineering Insiders Aligned With All Shareholders?
深圳新產業生物醫藥股份有限公司的內部人士是否與所有股東保持一致?
Since Shenzhen New Industries Biomedical Engineering has a market capitalisation of CN¥50b, we wouldn't expect insiders to hold a large percentage of shares. But we do take comfort from the fact that they are investors in the company. We note that their impressive stake in the company is worth CN¥9.4b. This totals to 19% of shares in the company. Enough to lead management's decision making process down a path that brings the most benefit to shareholders. Very encouraging.
由於深圳新產業生物醫藥股份有限公司的市值爲500億元人民幣,我們不會期望內部人士持有大量股份。但我們從他們是公司的投資者這個事實中得到了一些安慰。我們注意到,他們在公司的持股中所佔比例值94億元,佔公司股份總數的19%。這足以引導管理層做出對股東最有益的決策。非常鼓舞人心。
Should You Add Shenzhen New Industries Biomedical Engineering To Your Watchlist?
你應該將深圳新產業生物醫藥股份有限公司加入你的自選嗎?
For growth investors, Shenzhen New Industries Biomedical Engineering's raw rate of earnings growth is a beacon in the night. This EPS growth rate is something the company should be proud of, and so it's no surprise that insiders are holding on to a considerable chunk of shares. On the balance of its merits, solid EPS growth and company insiders who are aligned with the shareholders would indicate a business that is worthy of further research. It is worth noting though that we have found 1 warning sign for Shenzhen New Industries Biomedical Engineering that you need to take into consideration.
對於成長類投資者來說,深圳新產業的每股收益增長速度是一個指南燈。這種EPS增長速度是公司應該引以爲傲的,所以並不奇怪內部人士持有相當數量的股份。從其優點來看,強勁的EPS增長和與股東利益保持一致的公司內部人士表明了一個值得進一步研究的企業。需要注意的是,我們發現有1個深圳新產業的警告信號需要考慮。
There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a tailored list of Chinese companies which have demonstrated growth backed by significant insider holdings.
總有可能買入不增長收益且內部人士不購買股票的股票。但是對於那些認爲這些重要指標的人,我們鼓勵您查看具有這些特徵的公司清單。您可以獲得重點推薦的中國公司列表,這些公司證明了內部人員持股支持的增長。
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
請注意,本文討論的內部交易是指在相關司法管轄區中報告的交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。